Dr. Gabrielle Silver has been named CEO of Bioscript Group to help the company expand its scientific communications services for its international pharmaceutical clients.
The CEO graduated from the University of London with a MBBS and the University of Bristol with a BSc in Anatomical Science.
“Dr. Gabrielle Silver has been named CEO of Bioscript Group to help the company expand its scientific communications services for its international pharmaceutical clients“
Silver’s last position was as CEO of CHS Healthcare, where she supervised fast business growth and led an acquisition by Acacium Group. In addition to her vast experience in healthcare communications, Silver has non-executive directorships at the Royal National Orthopaedic Hospital NHS Trust and is a director at Opiant Pharmaceuticals.
Andrew Medley, founder of Bioscript, said “Our 5-year investment plan started in 2021 when we acquired Fortis, Meridian and Valid Insight. Bringing these excellent organisations together has enabled the creation of new capabilities across our business.”
“Gaby shares our vision for developing a market leading business, with specialist capabilities at the core and building an environment where our staff can develop and deliver their best work for their clients.”
Gabrielle Silver expressed her thoughts on the life science sector, which she described as “delivering a higher volume of launches, each with more technical and niche needs – we are seeing real transformation in the commercialisation service offering to better meet these needs. I think the team is in a fantastic position to further translate their expertise into value creation across the drug development lifecycle.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.See all the latest jobs in Healthcare Communications